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Association of polygenic risk for 
major psychiatric illness with 
subcortical volumes and white 
matter integrity in UK Biobank
L. M. Reus1, X. Shen1, J. Gibson1, E. Wigmore1, L. Ligthart2, M. J. Adams1, G. Davies3, 
S. R. Cox3,4, S. P. Hagenaars1,3,4, M. E. Bastin3, I. J. Deary3,4, H. C. Whalley1 & A. M. McIntosh1,3
Major depressive disorder (MDD), schizophrenia (SCZ) and bipolar disorder (BP) are common, disabling 
and heritable psychiatric diseases with a complex overlapping polygenic architecture. Individuals 
with these disorders, as well as their unaffected relatives, show widespread structural differences in 
corticostriatal and limbic networks. Structural variation in many of these brain regions is also heritable 
and polygenic but whether their genetic architecture overlaps with that of major psychiatric disorders 
is unknown. We sought to address this issue by examining the impact of polygenic risk of MDD, SCZ, 
and BP on subcortical brain volumes and white matter (WM) microstructure in a large single sample 
of neuroimaging data; the UK Biobank Imaging study. The first release of UK Biobank imaging data 
comprised participants with overlapping genetic data and subcortical volumes (N = 978) and WM 
measures (N = 816). The calculation of polygenic risk scores was based on genome-wide association 
study results generated by the Psychiatric Genomics Consortium. Our findings indicated no statistically 
significant associations between either subcortical volumes or WM microstructure, and polygenic risk 
for MDD, SCZ or BP. These findings suggest that subcortical brain volumes and WM microstructure may 
not be closely linked to the genetic mechanisms of major psychiatric disorders.
Major depressive disorder (MDD), schizophrenia (SCZ) and bipolar disorder (BP) are major psychiatric disor-
ders affecting between 1% and 13% of the general population1,2. Twin and family studies find a strong genetic con-
tribution to all three of these disorders3,4 and genome-wide association studies (GWAS) suggest that these effects 
are conferred by the cumulative impact of many loci, each of small effect5–8. Whilst progress in identifying the 
specific risk-conferring loci in SCZ has proved highly productive5, progress in BD and MDD has been slower6,7. 
Several strategies may accelerate the discovery of risk-loci, including the use of quantitative traits such as brain 
structure and connectivity.
Brain structure and connectivity measures have been shown to be heritable quantitative traits, with high 
heritabilities reported for both subcortical volumes (44–88%)9 and white matter (WM) integrity (53–90%)10. 
Furthermore, several genetic variants that influence brain structure have been identified11,12. Subcortical brain 
volume and WM microstructure abnormalities in corticostriatal and limbic networks have also been shown to 
distinguish individuals with SCZ, BD and MDD from controls in several studies, albeit with some inconsisten-
cies13–18. Differences between patients and controls in global measures of WM microstructure, diffusion tensor 
imaging (DTI) biomarkers, fractional anisotropy (FA), and mean diffusivity (MD), have been more consistently 
reported in these disorders19–24, and could suggest wide-spread WM integrity reductions.
Together, these volumetric and WM brain differences potentially describe a network of abnormality associated 
with major psychiatric illness. This network may have an important mechanistic role in the development of these 
disorders. This possibility is supported by several studies that show an association between brain structure and 
genetic liability for psychiatric disorders, though due to the cost of imaging these samples are typically an order 
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of magnitude smaller in size than the GWAS that preceded them. Notably, Van Scheltinga et al.25 (NSCZ = 152, 
Nhealthy = 142) found higher polygenic risk for SCZ to be modestly (R2 = 0.048) associated with smaller total 
brain volume, while Caseras et al.26 (Nhealthy = 274) reported a negative association between polygenic risk scores 
(PGRS) for SCZ and BP, and globus pallidus and amygdala grey matter (GM) volumes. Similar results have been 
found for the association between less optimal WM microstructure and greater genetic liability for SCZ25,27,28.
These associations have not been consistently reported; specifically, several studies have found no association 
between subcortical volumes and polygenic risk for MDD and SCZ29–31. However, these studies have used dif-
fering methodologies (i.e., multi-scanner study31 N = 11,840, from 22 studies) with relatively small sample sizes 
(Nhealthy29 = 438, Nhealthy30 = 122), which may contribute to inconsistencies in findings.
The current study sought to investigate the genetic relationship between major mental disorders and structural 
brain measures in a single large quality-controlled dataset using the same scanner and the same analysis pipelines. 
We used newly acquired data from the first release of the UK Biobank Imaging study to examine whether struc-
tural imaging measures, including subcortical volumes (N = 978) and WM microstructure measures (N = 816), 
were associated with genetic risk of MDD, SCZ, and BP32 (http://www.ukbiobank.ac.uk). We hypothesized that 
higher polygenic risk for these disorders would be associated with decreased volumetric and WM integrity meas-
ures in specifically corticostriatal and limbic networks.
Methods
Study population. The first release of UK Biobank imaging data consisted of 4,446 subjects (Nfemales/
Nmales = 2,342/2,104; mean age ± s.d. = 55.52 ± 7.62 years; age range = 40–70 years) with quality-checked volu-
metric and DTI data for the analysis (conducted by UK Biobank, Brain Imaging Documentation V1.1, http://
www.ukbiobank.ac.uk)33. In the current study, subjects were excluded if they did not provide genetic data, or 
if they were known to have participated in studies from the Psychiatric Genomics Consortium (PGC) GWAS 
dataset as this was used to construct the polygenic risk scores (PGRS). In total, the volumetric analysis included 
978 subjects (Nfemales/Nmales = 499/479; mean age ± s.d. = 55.32 ± 7.38 years; age range = 40–70 years) and the DTI 
analysis included 816 subjects (Nfemales/Nmales = 413/403; mean age ± s.d. = 55.49 ± 7.26 years; age range = 40–70 
years). Sample overlap (individuals included in both the DTI and volumetric analysis) included N = 816 par-
ticipants and the volumetric analysis included N = 162 extra participants. In addition, a sensitivity analysis was 
performed where we imposed internal imaging quality checks, excluding individuals whose subcortical volume 
or FA values were greater than three standard deviations above or below the mean for that measure. The sensitiv-
ity analysis, further referred to as the sample excluding outliers, included 892 (exclusion of 86 subjects; Nfemales/
Nmales = 477/415; mean age ± s.d. = 55.29 ± 7.31 years; age range = 40–70 years) and 733 (exclusion of 83 subjecs; 
Nfemales/Nmales = 373/360; mean age ± s.d. = 55.31 ± 7.22 years; age range = 40–70 years) subjects for the volumet-
ric and DTI analysis respectively. Sample overlap for the sample excluding outliers included N = 679, and the vol-
umetric analysis included 213 unique observations, whereas the DTI analysis included 54 unique observations.
This study has been approved by the National Health Service (NHS) Research Ethics Service (approval let-
ter dated 17th June 2011, reference: 11/NW/0382), and by the UK Biobank Access Committee (Project #4844). 
All experiments were performed in accordance with guidelines and regulations from these committees. Written 
informed consent was obtained from each subject.
Genotyping and derivation of polygenic risk scores. Procedures for DNA collection and genotyping 
in UK Biobank have been described previously by Hagenaars et al.34. Subjects were excluded from the PGRS 
analysis if they had a non-British ancestry, gender mismatch, relatedness (r > 0.044), and genotype missingness 
bigger than 2%.
PGRS for the three traits of interest (i.e., MDD, SCZ, BP) were created using PRSice35. For each subject PGRS 
were calculated by summing the number of risk alleles weighted by the strength of its association with the trait 
of interest. The strength of this association has been calculated previously by the PGC (PGC2 for SCZ)5,7,8. Prior 
to calculating the PGRS, single nucleotide polymorphisms (SNPs) were excluded if they had a minor allele fre-
quency less than 1%, deviated significantly from Hardy-Weinberg equilibrium (p < 1 × 10−6) in the total sample 
of founder individuals, or had a call rate of less than 99%. The remaining SNPs were used to calculate 15 mul-
tidimensional scaling (MDS) ancestry components (to account for population structure). For the main results, 
the SNP inclusion threshold was set as p ≤ 0.5, as Purcell et al.36 and studies following this work, have shown that 
this threshold is generally the most predictive of case-control status in subsequent studies5–8. Using the p ≤ 0.5 
SNP inclusion threshold, 631,763, 5,422,836 and 1,283,324 SNPs (after LD pruning) were included for the calcu-
lation of MDD-PGRS, SCZ-PGRS and BP-PGRS, respectively. Results generated by a SNP inclusion threshold of 
p ≤ 0.01, p ≤ 0.05, p ≤ 0.1 and p ≤ 1.0 are reported in supplementary materials.
Image acquisition and Neuroimaging data pre-processing. Procedures for image acquisition and 
pre-processing have been performed by UK Biobank, and are available on the UK Biobank website (http://
www.ukbiobank.ac.uk/), and have been documented previously33,37. In short, images were collected in Cheadle 
Manchester on a Siemens Skyra 3.0 T scanner (Siemens Medical Solutions, Germany) with a 32-channel head coil 
(https://www.healthcare.siemens.com/magnetic-resonance-imaging). T1-weighted scans were acquired using a 
3D MPRAGE (resolution 1 mm3 isotropic voxels) sequence, and diffusion-weighted (DW) scans were acquired 
with a monopolar Steejskal-Tanner pulse sequence and multi-shell acquisition (b0 = 0 s/mm2, b = 1,000 s/mm2, 
b = 2,000 s/mm2). Images were preprocessed and analysed with the FMRIB Software Library (FSL) (http://fsl.
fmrib.ox.ac.uk/fsl). More detailed information is reported in the supplementary materials.
Statistical analysis. All analyses were performed using R (version 3.2.3) in the Linux environment 
(R Development Core Team, 2010). To examine whether higher PGRS were associated with globally poor WM 
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microstructure, general components for FA (gFA) and MD (gMD) across the 27 WM tracts were calculated37. 
Latent measures, explaining a portion of variance WM structure, were calculated for both FA and MD by extract-
ing the scores on the first unrotated components, using a principal component analysis (PCA) on the 27 WM 
tracts. The first components accounted for a mean of 44.82% and 41.73% of total variance in FA and, 47.45% and 
45.35% in MD, in the sample including and excluding outliers respectively (loadings of tracts on the first latent 
component > 0.15). To examine whether higher PGRS were selectively associated with poor WM structure in a 
certain classification, this PCA was also performed separately for groups of different categories of WM tracts, 
including association (inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, superior longitudinal 
fasciculus, uncinate fasciculus, cingulum), projection (forceps minor, forceps major, corticospinal tracts, acous-
tic radiation, medial lemniscus, middle cerebellar peduncle) and thalamic radiation fibers, separately37 (sample 
including outliers: variance explained = 54.52%, 38.68% and 61.92% respectively for each subset, and loading of 
first component > 0.33; sample excluding outliers: variance explained = 60.05%, 32.05% and 72.05% respectively 
for each subset and loading of first component > 0.27).
For bilateral brain regions, associations between the three PGRS and each imaging measure were examined 
using a repeated measure linear mixed-effects analysis, modelling hemisphere as a random factor (where the 
PGRS * hemisphere interaction itself was found to be non-significant). For unilateral structures (e.g. total GM 
volume, forceps major, forceps minor and middle cerebellar peduncle), and those where there was a significant 
interaction between PGRS and hemisphere, associations were analysed as single structures without repeated 
measurements and without hemisphere as a separate term in the model.
For all models, additional fixed effects included age, age2, gender, genotype batch, genotype array and 15 
ancestry-informative MDS components. Intracranial volume, calculated as the sum of WM, GM and ventricular 
CSF, was also modelled as a fixed effect in the analysis of subcortical volumes in order to adjust for differences 
in overall brain size. PGRS and imaging measures were scaled to zero mean and unitary standard deviation. 
Standardised Beta values are reported throughout results. Results were corrected for multiple comparisons 
using a false discovery rate (FDR) correction38. Nagelkerke’s R2 was used to estimate the proportion of variation 
explained by PGRS.
Post-hoc positive control analyses, with age as an independent variable and each of the brain measures as 
dependent variable, were performed in order to test the sensitivity of UK Biobank imaging data, by verifying that 
we could replicate the widely reported negative associations between many structural brain measures and age 
(including those reported previously in an overlapping sample in UK Biobank)37. Fixed effects included gender 
for all structures, and side of hemisphere for lateralized structures only.
Results
PGRS and total brain and subcortical volumes. No significant associations were observed between 
PGRS (MDD, SCZ, or BP) at the threshold of p ≤ 0.5 and total GM, WM or CSF volume, in samples including 
or excluding outliers (Table 1). Furthermore, no significant associations were found between any of the three 
sets of PGRS and total GM, WM and CSF volume for any of the other PGRS p-value thresholds (all β < 0.054; all 
puncorrected and p FDR > 0.05) (Table S1).
A modest negative association was observed between thalamus volumes and the polygenic risk for SCZ at the 
threshold of p ≤ 0.05, p ≤ 0.1, p ≤ 0.5 and p ≤ 1.0 (β range = − 0.043–− 0.039; puncorrected = 0.052, puncorrected = 0.030, 
puncorrected = 0.054, puncorrected = 0.048 for all PGRS thresholds respectively) (Table 1 and S3). However, following 
FDR-correction no significant associations were found between PGRS (MDD, SCZ, or BP) at the threshold of 
p ≤ 0.5 and all subcortical volumes, before and after exclusion of outliers (Table 1). These results were unchanged 
at the other p-value thresholds (Tables S2, S3 and S4). For subcortical volumetric measures, no significant PGRS * 
hemisphere interactions were found; therefore, all analyses of bilateral structures could be conducted using a 
repeated measures design with hemisphere as a repeated factor. Mean values of the subcortical volumes are pre-
sented in supplementary Table S15.
PGRS and general and tract-specific diffusion measures. Associations between PGRS (MDD, SCZ, BP) 
and measures of general WM microstructure (gFA and gMD) were not significant (gFA β range = − 0.048–0.017; 
p range = 0.216–0.771, gMD β range = − 0.047–0.031; p range = 0.181–0.985) (Tables 2 and 3). Moreover, when 
gFA and gMD were calculated separately for projection, association, and thalamic radiation fibres, there remained 
no signification association between these measures and PGRS for MDD, SCZ and BP at p ≤ 0.5 threshold 
(Tables 2 and 3). These findings were similar at other p-value thresholds (Tables S5 and S6).
Trend-wise associations were observed between some polygenic MDD risk scores and MD values in the ante-
rior thalamic radiation, a group of WM fibers connecting frontal regions to anterior and middle nuclear groups of 
the thalamus (β = 0.084; p-FDR = 0.085, β = 0.088; p-FDR = 0.061, β = 0.086; p-FDR = 0.065 for PGRS threshold 
p ≤ 0.01, p ≤ 0.05 and p ≤ 0.5 respectively) (Tables S9 and S10). Polygenic MDD, SCZ or BP risk was also not 
significantly associated with other individual tract-specific water diffusion measures in the sample including 
(N = 816) and excluding outliers (N = 733) (Tables S7 and S9). These results were again similar for PGRS at the 
other thresholds (Tables S8 and S10).
No significant PGRS * hemisphere interactions were found for the majority of individual tract water diffu-
sion values, and therefore analyses on bilateral structures were conducted as a repeated measure. However, the 
SCZ-PGRS * hemisphere interaction was found to be significant for FA values in the parahippocampal portion of 
the cingulum (connecting orbitofrontal regions to the hippocampus) in the sample including outliers (β = − 0.052; 
pcorrected = 0.032). We therefore conducted tests of this association with SCZ-PGRS separately for each later-
alised structure for this region. However, these were also not significant for FA in either the left (β = − 0.040; 
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puncorrected = 0.262) or right (β = − 0.079; puncorrected = 0.029) parahippocampal portion of the cingulum, follow-
ing FDR correction. Mean values of the tract-specific water diffusion measures are presented in supplementary 
Table S16.
Age-related effects in structural brain measures. We additionally performed a post-hoc validation 
analysis in order to verify that despite our lack of polygenic associations we could indeed replicate the widely 
reported negative associations between structural brain measures and age. We conducted our analyses using age 
as an independent variable and each of the brain measures as dependent variable. As expected, total GM and WM 
volumes showed a significant negative association with age, whereas this association was positive for total CSF 
volume (Table S11). Additionally, highly significant (β = − 0.392–− 0.166; p-FDR < 0.001) negative associations 
were reported between age and the majority of subcortical volumes. Amygdala volumes were not significant 
associated with age (Table S12).
The association between age and WM microstructure has been examined in a larger sample (N = 3,513) of the 
UK Biobank dataset37. Age effects on WM in this sample with overlapping MRI and genetic data are broadly in 
agreement with this previous study, as indicated by a negative association between age and WM microstructure 
quality (Tables S13 and S14).
Including outliers (N = 978) Excluding outliers (N = 892)
Beta: z ratio (S.D.) t statistic p -uncorr. p-FDR R2 Beta: z ratio (S.D.) t statistic p -uncorr p-FDR R2
MDD-PGRS
 GM volume 0.001 (0.027) 0.049 0.961 1.000 0.000 − 0.001 (0.029) − 0.051 0.959 1.000 0.000
 WM volume − 0.007 (0.027) − 0.262 0.793 1.000 0.005 − 0.026 (0.028) − 0.913 0.362 1.000 0.067
 CSF volume 0.042 (0.030) 1.392 0.164 0.492 0.174 0.054 (0.031) 1.748 0.081 0.243 0.289
 Caudate 0.026 (0.026) 0.970 0.332 1.000 0.066 0.031 (0.028) 1.119 0.264 1.000 0.099
 Hippocampus − 0.002 (0.026) − 0.082 0.935 1.000 0.000 − 0.003 (0.026) − 0.130 0.896 1.000 0.001
 Pallidum 0.003 (0.027) 0.107 0.915 1.000 0.001 − 0.013 (0.027) − 0.466 0.641 1.000 0.016
 Thalamus − 0.012 (0.020) − 0.611 0.541 1.000 0.015 − 0.025 (0.020) − 1.218 0.223 1.000 0.060
 Amygdala − 0.000 (0.027) − 0.010 0.992 1.000 0.000 0.015 (0.027) 0.551 0.582 1.000 0.023
 Nucleus accumbens − 0.019 (0.026) − 0.742 0.458 1.000 0.038 − 0.030 (0.027) − 1.126 0.260 1.000 0.093
 Putamen 0.007 (0.022) 0.309 0.757 1.000 0.005 − 0.010 (0.023) − 0.451 0.652 1.000 0.011
SCZ-PGRS
 GM volume −0.012 (0.028) −0.444 0.657 1.000 0.001 − 0.018 (0.029) − 0.613 0.540 1.000 0.033
 WM volume 0.000 (0.027) 0.032 0.974 1.000 0.000 − 0.004 (0.029) − 0.147 0.883 1.000 0.002
 CSF volume 0.049 (0.030) 1.616 0.106 0.319 0.236 0.063 (0.031) 2.029 0.043 0.128 0.397
 Caudate − 0.003 (0.026) − 0.101 0.919 1.000 0.001 − 0.016 (0.028) − 0.559 0.577 1.000 0.025
 Hippocampus − 0.001 (0.025) − 0.044 0.965 1.000 0.000 0.015 (0.026) 0.558 0.577 1.000 0.021
 Pallidum − 0.015 (0.027) − 0.578 0.564 1.000 0.024 − 0.022 (0.027) − 0.795 0.427 1.000 0.047
 Thalamus − 0.039 (0.020) − 1.929 0.054 0.378 0.149 − 0.039 (0.020) − 1.947 0.052 0.363 0.155
 Amygdala 0.015 (0.026) 0.558 0.577 1.000 0.022 0.025 (0.028) 0.912 0.362 1.000 0.063
 Nucleus accumbens − 0.024 (0.026) − 0.924 0.356 1.000 0.058 − 0.023 (0.027) − 0.843 0.400 1.000 0.053
 Putamen 0.005 (0.022) 0.211 0.833 1.000 0.002 − 0.016 (0.023) − 0.672 0.502 1.000 0.025
BP-PGRS
 GM volume 0.003 (0.027) 0.093 0.926 1.000 0.001 − 0.012 (0.029) − 0.405 0.686 1.000 0.013
 WM volume 0.000 (0.026) 0.019 0.985 1.000 0.000 0.006 (0.028) 0.229 0.819 1.000 0.004
 CSF volume − 0.007 (0.029) − 0.246 0.805 1.000 0.005 0.007 (0.030) 0.216 0.829 1.000 0.004
 Caudate 0.017 (0.026) 0.653 0.514 1.000 0.029 0.007 (0.028) 0.245 0.806 1.000 0.005
 Hippocampus 0.024 (0.025) 0.963 0.336 1.000 0.058 0.011 (0.026) 0.421 0.674 1.000 0.012
 Pallidum − 0.000 (0.026) − 0.009 0.993 1.000 0.000 − 0.023 (0.027) − 0.865 0.387 1.000 0.054
 Thalamus 0.010 (0.020) 0.517 0.605 1.000 0.010 0.005 (0.020) 0.249 0.803 1.000 0.002
 Amygdala 0.030 (0.026) 1.158 0.247 1.000 0.091 0.032 (0.027) 1.186 0.236 1.000 0.103
 Nucleus accumbens − 0.008 (0.026) − 0.296 0.767 1.000 0.006 − 0.017 (0.027) − 0.626 0.532 1.000 0.028
 Putamen 0.025 (0.022) 1.133 0.257 1.000 0.061 0.015 (0.023) 0.659 0.510 1.000 0.023
Table 1. Association of PGRS (MDD, SCZ or BP) at ≤ 0.5 with total grey matter, white matter, 
cerebrospinal fluid, and subcortical volumes, in sample including and excluding outliers.  MDD: 
major depressive disorder, SCZ: schizophrenia, BP: bipolar disorder, PGRS: polygenic risk scores, uncorr.: 
uncorrected, FDR: false discovery rate, GM: grey matter, WM: white matter, CSF: cerebrospinal fluid, S.D.: 
standard deviation. Controlled for age, age2, gender, genotype batch and array, and 15 MDS components. 
Additional fixed effects for subcortical volumes include intracranial volume and side of hemisphere. 
R2 = estimate of variance explained by PGRS in %.
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Discussion
Structural brain abnormalities in corticostriatal and limbic structures are thought to play an important role in the 
pathophysiology of common disabling psychiatric disorders, such as MDD, SCZ and BP. Since these structural 
brain abnormalities have been observed in unaffected relatives of patients and have been shown to be heritable 
quantitative traits, the current study sought to test the impact of the polygenic liability for MDD, SCZ, or BP on 
subcortical brain volumes and WM microstructure in individuals from a population-based study. Contrary to 
our predictions, we found no evidence for an association between polygenic risk for MDD, SCZ and BP and either 
subcortical brain regions or WM microstructure. These findings provide no support for the hypothesis that the 
polygenic liability for MDD, SCZ and BP is linked to changes in subcortical brain volumes and WM microstruc-
ture in major psychiatric illness.
Our findings are in contrast to many published studies that report a relationship between subcortical GM 
volume and PGRS for psychiatric disorders25,26. However, these studies have generally been smaller than UK 
Including outliers (N = 816) Excluding outliers (N = 733)
Beta: z ratio (S.D.) t statistic p R2 Beta: z ratio (S.D.) t statistic p R2
MDD-PGRS
 gFA 0.017 (0.036) 0.476 0.634 0.030 − 0.011 (0.038) − 0.291 0.771 0.012
 gFA Association 0.037 (0.036) 1.026 0.305 0.139 0.011 (0.039) 0.296 0.767 0.013
 gFA Projection − 0.020 (0.036) − 0.560 0.576 0.041 − 0.049 (0.038) − 1.297 0.195 0.244
 gFA Thalamic 0.002 (0.037) − 0.043 0.966 0.000 − 0.025 (0.039) − 0.650 0.516 0.063
SCZ-PGRS
 gFA − 0.028 (0.036) − 0.768 0.443 0.078 − 0.048 (0.039) − 1.237 0.216 0.230
 gFA Association − 0.020 (0.036) − 0.559 0.576 0.041 − 0.040 (0.039) − 1.034 0.302 0.161
 gFA Projection − 0.034 (0.036) − 0.947 0.344 0.116 − 0.036 (0.038) − 0.947 0.344 0.132
 gFA Thalamic − 0.032 (0.037) 0.885 0.376 0.105 − 0.059 (0.039) − 1.521 0.129 0.348
BP-PGRS
 gFA − 0.013 (0.036) − 0.367 0.714 0.017 − 0.014 (0.038) − 0.370 0.711 0.019
 gFA Association − 0.016 (0.036) − 0.442 0.659 0.025 − 0.017 (0.038) − 0.445 0.657 0.028
 gFA Projection − 0.023 (0.035) − 0.665 0.506 0.055 − 0.014 (0.037) − 0.369 0.712 0.019
 gFA Thalamic − 0.000 (0.036) 0.0223 0.982 0.000 − 0.008 (0.038) − 0.214 0.831 0.008
Table 2.  Association of PGRS (MDD, SCZ or BP) at p ≤ 0.5 with gFA and gFA for association, projection 
and thalamic WM fibers.  FA: fractional anisotropy, WM: white matter, g: general component, MDD: 
major depressive disorder, SCZ: schizophrenia, BP: bipolar disorder, PGRS: polygenic risk scores, S.D.: 
standard deviation. Controlled for age, age2 and gender, genotype batch and array, and 15 MDS components. 
R2 = estimate of variance explained by PGRS in %.
Including outliers (N = 816) Excluding outliers (N = 733)
Beta: z ratio (S.D.) t statistic p R2 Beta: z ratio (S.D.) t statistic p R2
MDD-PGRS
 gMD − 0.047 (0.035) − 1.340 0.181 0.224 − 0.028 (0.037) − 0.756 0.450 0.079
 gMD Association − 0.053 (0.036) − 1.484 0.138 0.281 − 0.030 (0.038) − 0.810 0.418 0.093
 gMD Projection − 0.053 (0.037) − 1.417 0.157 0.277 − 0.042 (0.039) − 1.075 0.283 0.179
 gMD Thalamic − 0.031 (0.034) − 0.907 0.365 0.094 − 0.017 (0.035) − 0.479 0.632 0.029
SCZ-PGRS
 gMD − 0.018 (0.035) − 0.503 0.615 0.031 0.001 (0.037) 0.019 0.985 0.000
 gMD Association − 0.006 (0.036) − 0.179 0.858 0.004 0.005 (0.038) 0.121 0.903 0.002
 gMD Projection − 0.035 (0.037) − 0.951 0.342 0.124 − 0.021 (0.040) − 0.517 0.606 0.042
 gMD Thalamic − 0.026 (0.034) − 0.777 0.438 0.068 0.003 (0.036) 0.084 0.933 0.001
BP-PGRS
 gMD 0.014 (0.034) 0.408 0.684 0.020 0.031 (0.036) 0.865 0.387 0.099
 gMD Association 0.017 (0.035) 0.500 0.617 0.030 0.032 (0.037) 0.874 0.383 0.104
 gMD Projection 0.003 (0.036) 0.082 0.935 0.000 − 0.009 (0.039) 0.232 0.817 0.008
 gFMDThalamic 0.011 (0.033) 0.328 0.743 0.012 0.032 (0.035) 0.933 0.351 0.104
Table 3.  Association of PGRS (MDD, SCZ or BP) at p ≤ 0.5 with gMD and gMD for association, projection 
and thalamic WM fibers. MD: mean diffusivity, WM: white matter, g: general factor, MDD: major depressive 
disorder, SCZ: schizophrenia, BP: bipolar disorder, PGRS: polygenic risk scores, S.D.: standard deviation. 
Controlled for age, age2 and gender, genotype batch and array, and 15 MDS components. R2 = estimate of 
variance explained by PGRS in %.
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Biobank (N25,26 < 294), increasing the risk of false positive results. In a complementary approach to our study, 
schizophrenia polygenic risk scores and linkage disequilibrium (LD) score regression have been used to test 
for shared genetic architecture between subcortical brain volumes and schizophrenia (N = 11,840)31. As in the 
current study, this study also reported a lack of overlapping genetic architecture between SCZ and subcortical 
volumes31. Moreover, Van Scheltinga et al.’s25 result of a significant association between polygenic liability for 
SCZ and total brain volume could not be replicated in another study30. Holmes et al.29 (N = 438) also reported no 
association between MDD-PGRS and amygdala volume29. Here we extend these findings to SCZ, BD and MDD 
and across a range of subcortical measures (Table 1 and S1–S4) using a large, single scanner sample.
Only a few studies have been published regarding the association between genetic liability for psychiatric 
illness and WM integrity. No associations between WM integrity and polygenetic liability have been reported 
for BP, whereas polygenetic liability for MDD and SCZ have been reported to be associated with decreased WM 
integrity27,28. Furthermore, individuals at high genetic risk for psychiatric disorders, such as relatives of patients, 
have shown reduced WM integrity39–41. Conversely, our study found no relation between genetic liability for psy-
chiatric disorders and WM integrity (Tables 2 and 3 and S5–S10).
Our results provide no evidence for an association between PGRS and subcortical volumes and WM micro-
structure, however there are a number of limitations to this study that should be taken into account. Firstly, 
it is possible that any shared genetic architecture with brain structure was too small to detect in the current 
sample. Although our sample sizes (Nvolumetric/NDTI = 978/816) are large for imaging research, they are relatively 
small when compared to a typical PGRS study. A general limitation of PGRS is that they account for only a 
small proportion of total phenotypic variance, far short of their narrow sense heritability. The addition of further 
discovery GWA samples for MDD, SCZ and BD will improve the predictive accuracy of PGRS and alongside 
developments in imaging consortia, such as ENIGMA (http://enigma.ini.usc.edu/), will make it possible to test 
for smaller effects in future studies42. The current results may indicate that polygenic risk score associations with 
brain structure should be interpreted cautiously in smaller studies. Our findings should, however, be replicated to 
exclude the presence of a small genetic correlation between psychiatric disorder and brain structure and connec-
tivity measures. Moreover, UK Biobank is a mixed community population, including both healthy individuals, 
patients, and individuals without clinical records. Although some previous studies did find associations in both 
healthy individuals and patients separately25,26, analysing these groups together could have resulted in differences 
between the current and previous findings. To exclude the possibility of different genetic associations across clin-
ical groups, future research should analyse cases and controls separately. Additionally, previous studies included 
relatively young participants (age range = 18–35 years)25,26,29–31, whereas UK Biobank is a middle-older age study 
(age range = 40–70 years)32. Genetic associations between brain structure and major psychiatric disorders might 
be more difficult to detect in older populations, as older age groups might engender greater time for differential 
environmental exposure on the brain. Our results are, therefore, limited to the studied age range and should be 
replicated in independent studies. Furthermore, future work should also examine whether the genetic architec-
ture of other in vivo brain parameters, such as measures of cortical morphology43 and brain function, overlap with 
major mental illness.
In summary, the current study reports no evidence of shared genetic architecture between psychiatric disor-
ders and either subcortical brain volumes or WM integrity. Our results do not replicate the findings of several 
published studies with small sample sizes, but are supported by similar recent work, particularly in SCZ.
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